HSE Skyclarys Decision Looms for Friedreich's Ataxia Patients as Families Await Reimbursement Ruling
The HSE is preparing to make a critical decision on whether to reimburse Skyclarys (omaveloxolone), the first disease-modifying treatment for Friedreich's ataxia, for Irish patients, with families of those affected by the rare and progressive neurological condition watching anxiously as the health service weighs the drug's clinical benefits against its annual cost of approximately €280,000 per patient.
Background
Friedreich's ataxia is a rare, inherited, and progressive neurological condition that causes damage to the nervous system and the heart, leading to difficulties with coordination, balance, and speech, and ultimately to wheelchair dependence in most cases. The condition typically begins in childhood or adolescence and progresses over decades, with most patients requiring a wheelchair by their mid-twenties. There is no cure for Friedreich's ataxia, and until recently, treatment options were limited to managing symptoms and slowing the progression of complications.
Skyclarys (omaveloxolone), developed by Reata Pharmaceuticals and now marketed by Biogen, is the first drug to receive regulatory approval specifically for the treatment of Friedreich's ataxia. The European Medicines Agency approved the drug in 2023, and it has since been approved in the United States and several other countries. Clinical trials have demonstrated that Skyclarys can slow the progression of neurological decline in patients with Friedreich's ataxia, representing a significant advance in the treatment of a condition for which there were previously no disease-modifying options.
However, the drug's annual cost — approximately €280,000 per patient per year — has made it one of the most expensive treatments in the Irish healthcare system, and the HSE's National Centre for Pharmacoeconomics (NCPE) has been conducting a health technology assessment to determine whether the drug represents value for money for the Irish health system. The assessment process, which involves a detailed analysis of the drug's clinical evidence, cost-effectiveness, and budget impact, has been ongoing for several months.
Key Developments
The HSE is expected to make a decision on the reimbursement of Skyclarys in the coming weeks, following the completion of the NCPE's health technology assessment. Patient advocates and families of those affected by Friedreich's ataxia have been lobbying intensively for a positive decision, arguing that the drug represents the only meaningful treatment option for a devastating condition and that the cost, while high, must be weighed against the enormous burden of the disease on patients and their families.
Dr. Suzanne Crowe, a leading advocate for rare disease patients in Ireland, has called for greater transparency in the HSE's drug reimbursement process, arguing that the current system lacks the openness and accountability that patients and families deserve. Writing in the Irish Medical Times, Dr. Crowe argued that the process for assessing rare disease drugs needs to be reformed to better reflect the specific challenges of evaluating treatments for conditions that affect small numbers of patients and for which the clinical evidence base is necessarily limited.
The Friedreich's Ataxia Society of Ireland has been coordinating the advocacy campaign for Skyclarys reimbursement, working with patient families, healthcare professionals, and politicians to make the case for a positive HSE decision. The society has highlighted the devastating impact of the condition on young people and their families, and has argued that the availability of a disease-modifying treatment represents a once-in-a-generation opportunity to change the trajectory of the condition for Irish patients.
Why It Matters
The Skyclarys decision matters because it will determine whether Irish patients with Friedreich's ataxia have access to the only disease-modifying treatment available for their condition. For the approximately 150 people in Ireland living with Friedreich's ataxia, the availability of Skyclarys could mean the difference between a life of progressive disability and a life in which the progression of the condition is slowed and quality of life is maintained for longer. The stakes could not be higher for the patients and families involved.
The decision also matters as a test of Ireland's approach to rare disease drug reimbursement more broadly. Ireland has historically been slow to reimburse new medicines compared to other European countries, and the Skyclarys case has highlighted the need for a more responsive and transparent process that can make timely decisions on treatments for rare conditions. The government has committed to reforming the drug reimbursement process, and the Skyclarys decision will be an important test of whether that commitment is being delivered.
Local Impact
For the families of people with Friedreich's ataxia across Ireland — in Dublin, Cork, Galway, and in rural communities from Donegal to Kerry — the HSE's decision will have profound personal consequences. Many of these families have been following the Skyclarys approval process for years, and the prospect of a positive reimbursement decision has given them hope that their loved ones will be able to access a treatment that could meaningfully improve their quality of life. A negative decision would be devastating, and patient advocates have warned that it would undermine confidence in Ireland's commitment to rare disease patients.
What's Next
The HSE is expected to publish its decision on Skyclarys reimbursement in the coming weeks. If the decision is positive, the drug will be available to eligible patients through the HSE's Long-Term Illness Scheme, with the cost covered by the state. If the decision is negative, patient advocates have indicated that they will pursue all available avenues to challenge the decision, including engagement with the Minister for Health and, if necessary, legal action. The Friedreich's Ataxia Society of Ireland has also indicated that it will continue to engage with the HSE and the Department of Health to ensure that the needs of rare disease patients are properly considered in the reimbursement process.
